Home/Filings/4/0000950170-25-113130
4//SEC Filing

Zalevsky Jonathan 4

Accession 0000950170-25-113130

CIK 0000906709other

Filed

Sep 3, 8:00 PM ET

Accepted

Sep 4, 9:02 PM ET

Size

5.3 KB

Accession

0000950170-25-113130

Insider Transaction Report

Form 4
Period: 2025-09-02
Zalevsky Jonathan
Chief R&D Officer
Transactions
  • Sale

    Common Stock

    2025-09-02$30.10/sh485$14,59919,183 total
Footnotes (2)
  • [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]This transaction was executed in multiple trades at prices ranging from $30.00 to $30.28 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Documents

1 file

Issuer

NEKTAR THERAPEUTICS

CIK 0000906709

Entity typeother

Related Parties

1
  • filerCIK 0001789857

Filing Metadata

Form type
4
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 9:02 PM ET
Size
5.3 KB